Jennison Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-115,199
| Closed | -$89M | – | 613 |
|
|
2026
Q1 | $89M | Buy |
+115,199
| New | +$88.2M | 0.06% | 147 |
|
|
2024
Q3 | – | Sell |
-99,802
| Closed | -$105M | – | 625 |
|
|
2024
Q2 | $105M | Buy |
99,802
+66,281
| +198% | +$64.3M | 0.07% | 119 |
|
|
2024
Q1 | $32.3M | Buy |
+33,521
| New | +$31.9M | 0.02% | 284 |
|
|
2023
Q2 | – | Sell |
-28,090
| Closed | -$23.1M | – | 616 |
|
|
2023
Q1 | $23.1M | Buy |
+28,090
| New | +$21.2M | 0.02% | 311 |
|
|
2021
Q4 | – | Sell |
-1,805
| Closed | -$1.09M | – | 715 |
|
|
2021
Q3 | $1.09M | Buy |
+1,805
| New | +$1.12M | ﹤0.01% | 597 |
|
|
2021
Q2 | – | Sell |
-10,061
| Closed | -$4.76M | – | 716 |
|
|
2021
Q1 | $4.76M | Buy |
+10,061
| New | +$4.9M | ﹤0.01% | 479 |
|
|
2020
Q4 | – | Sell |
-66,884
| Closed | -$37.4M | – | 689 |
|
|
2020
Q3 | $37.4M | Sell |
66,884
-1,673
| -2% | -$1.01M | 0.03% | 226 |
|
|
2020
Q2 | $42.8M | Buy |
68,557
+22,157
| +48% | +$12.6M | 0.04% | 190 |
|
|
2020
Q1 | $22.7M | Buy |
+46,400
| New | +$19.1M | 0.03% | 240 |
|
|
2019
Q3 | – | Sell |
-3,332
| Closed | -$1.04M | – | 680 |
|
|
2019
Q2 | $1.04M | Sell |
3,332
-83
| -2% | -$27.6K | ﹤0.01% | 551 |
|
|
2019
Q1 | $1.4M | Buy |
+3,415
| New | +$1.41M | ﹤0.01% | 516 |
|
|
2018
Q2 | – | Sell |
-88,815
| Closed | -$30.6M | – | 703 |
|
|
2018
Q1 | $30.6M | Buy |
88,815
+13,022
| +17% | +$4.53M | 0.03% | 332 |
|
|
2017
Q4 | $28.5M | Sell |
75,793
-1,123,954
| -94% | -$455M | 0.03% | 344 |
|
|
2017
Q3 | $536M | Sell |
1,199,747
-93,116
| -7% | -$44.3M | 0.55% | 47 |
|
|
2017
Q2 | $635M | Buy |
1,292,863
+532,547
| +70% | +$233M | 0.67% | 41 |
|
|
2017
Q1 | $295M | Sell |
760,316
-1,156,625
| -60% | -$429M | 0.32% | 55 |
|
|
2016
Q4 | $704M | Sell |
1,916,941
-205,207
| -10% | -$78M | 0.79% | 33 |
|
|
2016
Q3 | $853M | Buy |
2,122,148
+91,223
| +4% | +$36.6M | 0.92% | 32 |
|
|
2016
Q2 | $709M | Sell |
2,030,925
-20,934
| -1% | -$8.06M | 0.78% | 35 |
|
|
2016
Q1 | $740M | Buy |
2,051,859
+35,832
| +2% | +$14.8M | 0.78% | 39 |
|
|
2015
Q4 | $1.09B | Buy |
2,016,027
+93,894
| +5% | +$50.9M | 1.07% | 25 |
|
|
2015
Q3 | $894M | Buy |
1,922,133
+189,407
| +11% | +$102M | 0.92% | 28 |
|
|
2015
Q2 | $884M | Buy |
+1,732,726
| New | +$846M | 0.81% | 35 |
|
Other funds holding REGN
Jennison Associates's REGN Position: Q2 2026 in Review
Jennison Associates sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 115,199 shares — an estimated $89M sold.
Jennison Associates first reported a position in REGN in Q2 2015 and held it in 23 quarters. The position peaked at $1.09B in Q4 2015. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Jennison Associates reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jennison Associates sold 115,199 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $89M.
- Jennison Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 23 quarters.
- Jennison Associates's Regeneron Pharmaceuticals position peaked at $1.09B in Q4 2015.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.